Roche licenses two of Inovio's early-stage DNA vaccines

Roche has bolstered its early-stage pipeline by entering a collaboration with small US biotech company Inovio Pharmaceuticals. Roche is paying $10m upfront for exclusive worldwide rights to two of Inovio's preclinical immunotherapies targeting prostate cancer and hepatitis B.